The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the Ohio State University Comprehensive Cancer Center to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedure and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: Optimally utilize and integrate the cancer center efforts extent within the ten colleges at The Ohio State University engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the CCC and at the community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the need of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments on cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The Ohio State University Comprehensive Cancer Center will undergo significant development during the coming years that will culminate in broadened interdisciplinary cancer research and cancer control programs. The Opening of the new Arthur G. James Cancer Hospital and Research Institute in 1989 will provide significant new resources to meet the needs of the 1990's and the twenty-first century as part of the nationwide effort to ultimately control cancer totally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-20
Application #
2086419
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-07-01
Project End
1995-06-30
Budget Start
1994-08-29
Budget End
1995-06-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kotlarek, Marta; Kubiak, Anna; Czetwerty?ska, Ma?gorzata et al. (2018) The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma. Int J Mol Sci 19:
Li, Feng; Malli, Ahmad; Cruz-Monserrate, Zobeida et al. (2018) Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts. World J Gastrointest Endosc 10:1-9
He, Huiling; Li, Wei; Yan, Pearlly et al. (2018) Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid 28:748-754
Moshiri, Jasmine; Kaur, Darpan; Hambira, Chido M et al. (2018) Identification of a Small Molecule Anti-biofilm Agent Against Salmonella enterica. Front Microbiol 9:2804
Serna, Vanida A; Wu, Xin; Qiang, Wenan et al. (2018) Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo. Endocr Relat Cancer 25:747-759
Dabrowski, Konrad; Miller, Mackenzie (2018) Contested Paradigm in Raising Zebrafish (Danio rerio). Zebrafish 15:295-309
Krok-Schoen, Jessica L; Fisher, James L; Baltic, Ryan D et al. (2018) White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival Among Older Adults. J Aging Health 30:863-881
Killian, Jackson A; Topiwala, Taha M; Pelletier, Alex R et al. (2018) FuSpot: a web-based tool for visual evaluation of fusion candidates. BMC Genomics 19:139
Sizemore, Gina M; Balakrishnan, Subhasree; Thies, Katie A et al. (2018) Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun 9:2783
Zeng, Rong; Liu, Yi; Jiang, Zhao-Jing et al. (2018) EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J Oncol :

Showing the most recent 10 out of 2602 publications